戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 purine recycling enzyme hypoxanthine-guanine phosphoribosyltransferase.
2 ounts for the allosteric inhibition of MtATP-phosphoribosyltransferase.
3 eficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase.
4 D biosynthetic enzymes, namely, nicotinamide phosphoribosyltransferase.
5 r catalysis in one of these enzymes, adenine phosphoribosyltransferase.
6  at the site of the upt gene encoding uracil phosphoribosyltransferase.
7 city is funnelled exclusively through uracil phosphoribosyltransferase.
8 -glucuronidase and cytosine deaminase/uracil phosphoribosyltransferase.
9 lic factors rather by the specificity of the phosphoribosyltransferase.
10 ovo pathway gene, nadC, encoding quinolinate phosphoribosyltransferase.
11 as a fluorescent substrate for yeast adenine phosphoribosyltransferase.
12 lytically poised reaction complex for type I phosphoribosyltransferases.
13 cores, an element common to all known purine phosphoribosyltransferases.
14 a structural theme found in all known purine phosphoribosyltransferases.
15  dehydrogenase (GAPDH), hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1), DNA-directed RNA po
16 nished by adding nicotinic acid (NA) in a NA phosphoribosyltransferase 1 (NAPRT1)-dependent manner, b
17 target HPRT1, the gene encoding hypoxanthine phosphoribosyltransferase-1 (HPRT1), and POU5F1, the gen
18 gulated (thymidine kinase, 2.9-fold; orotate phosphoribosyltransferase, 2.3-fold; uridine monophospha
19  for the specificity of hypoxanthine-guanine phosphoribosyltransferase, a key enzyme in the purine sa
20 e generated mice overexpressing nicotinamide phosphoribosyltransferase, a rate-limiting enzyme for NA
21 1778 is a specific inhibitor of nicotinamide phosphoribosyltransferase, a rate-limiting enzyme requir
22 d characterized physically, for their uracil phosphoribosyltransferase activity and for their ability
23 ing, bioinformatic analyses, and an assay of phosphoribosyltransferase activity in Mycobacterium smeg
24                 Indeed, the quinolinate (Qa) phosphoribosyltransferase activity of NadC from S. pyoge
25     B. burgdorferi showed low but detectable phosphoribosyltransferase activity with hypoxanthine eve
26 lation of pyr genes in vivo and their uracil phosphoribosyltransferase activity, which is catalyzed b
27 enhancing factor, known to have nicotinamide phosphoribosyltransferase activity.
28 show that a novel mycobacterial mannosylated phosphoribosyltransferase acts as a virulence and immuno
29 ccompanied by suppressed SIRT1, nicotinamide phosphoribosyltransferase, AGE receptor 1, and PPARgamma
30 hose without renal-risk variants; nicotinate phosphoribosyltransferase also displayed gene expression
31  circadian expression of NAMPT (nicotinamide phosphoribosyltransferase), an enzyme that provides a ra
32 rasite lacking hypoxanthine-xanthine-guanine phosphoribosyltransferase and a T. gondii cDNA library.
33 ities, Km values, and Vmax values of adenine phosphoribosyltransferase and of hypoxanthine phosphorib
34 The last two enzymes of the pathway, orotate phosphoribosyltransferase and orotidine-5-monophosphate
35 g MTA from the polyamine pathway via adenine phosphoribosyltransferase and recycling MTR to methionin
36 to FK866-mediated inhibition of nicotinamide phosphoribosyltransferase and stimulates glycolysis in c
37          Two of these, uridine kinase-uracil phosphoribosyltransferase and thymidine kinase, are uniq
38  is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some Pseudomonads, wit
39                        Purine and pyrimidine phosphoribosyltransferases and nucleoside N-ribosyl hydr
40                          SirT1, nicotinamide phosphoribosyltransferase, and NAD may, therefore, provi
41 Bacillus subtilis xpt gene encoding xanthine phosphoribosyltransferase, and the S-adenosyl-methionine
42 ily of salvage and biosynthetic enzymes, the phosphoribosyltransferases, and catalyzes the transfer o
43                            Using the adenine phosphoribosyltransferase (APRT(+)) --> APRT(-) forward
44 he contrary, we found no evidence of adenine phosphoribosyltransferase (APRT) activity when parasites
45  major parallel pathways mediated by adenine phosphoribosyltransferase (APRT) and guanine phosphoribo
46                                      Adenine phosphoribosyltransferase (APRT) deficiency is a rare, h
47                                      Adenine phosphoribosyltransferase (APRT) deficiency is a rare, h
48 ed and nontranscribed strands of the adenine phosphoribosyltransferase (APRT) gene in Chinese hamster
49 ations in the second intron of the adenosine phosphoribosyltransferase (APRT) gene in Chinese hamster
50 lification and overexpression of the adenine phosphoribosyltransferase (APRT) gene.
51 the CpG island upstream of the mouse adenine phosphoribosyltransferase (Aprt) gene.
52 nation between direct repeats at the adenine phosphoribosyltransferase (APRT) locus in ERCC1-deficien
53 iciently repaired in both strands of adenine phosphoribosyltransferase (APRT) locus, in either a tran
54                        Knockdown for adenine phosphoribosyltransferase (APRT) or nicotinamide phospho
55                                      Adenine phosphoribosyltransferase (APRT, EC 2.4.2.7) catalyzes t
56                                  The adenine phosphoribosyltransferase (APRTase) from Giardia lamblia
57                                      Adenine phosphoribosyltransferase (APRTase) is a widely distribu
58  and relies primarily on adenine and guanine phosphoribosyltransferases (APRTase and GPRTase) constit
59                Here, we developed an adenine phosphoribosyltransferase (APT)-based RNAi technology (A
60 ltered expression of a gene encoding adenine phosphoribosyltransferase (APT1), an enzyme that convert
61 sis has shown that the anthranilate synthase-phosphoribosyltransferase (AS-PRT) enzyme complex, invol
62                                              Phosphoribosyltransferase assays revealed that, in gener
63                                          ATP-phosphoribosyltransferase (ATP-PRT) is a hexameric enzym
64                                          ATP-phosphoribosyltransferase (ATP-PRT), as the first enzyme
65                                          ATP-phosphoribosyltransferase (ATP-PRT), the first enzyme of
66 osteric domain.Active and inactive state ATP-phosphoribosyltransferases (ATP-PRTs) are believed to ha
67 of biomass in E. coli were identified as ATP phosphoribosyltransferase, ATP synthase, methylene-tetra
68                             Unlike all known phosphoribosyltransferases, beta-RFA-P synthase catalyze
69 cleotide binding to PyrR is similar to other phosphoribosyltransferases, but Mg2+ binding differs.
70                                       Purine phosphoribosyltransferases catalyze the Mg2+ -dependent
71                                        MtATP-phosphoribosyltransferase catalyzes the first and commit
72             Hereditary deficiency of adenine phosphoribosyltransferase causes 2,8-dihydroxyadenine (2
73  and activity of a cytosine deaminase-uracil phosphoribosyltransferase (CD-UPRT) fusion enzyme expres
74 diac-specific overexpression of nicotinamide phosphoribosyltransferase (cNAMPT) as examples.
75 he hydroxybenzimidazole synthase BzaAB/BzaF, phosphoribosyltransferase CobT, and three methyltransfer
76 void of NaMN:5,6-dimethylbenzimidazole (DMB) phosphoribosyltransferase (CobT) activity was used to is
77 otide (NaMN):5,6-dimethylbenzimidazole (DMB) phosphoribosyltransferase (CobT) from Salmonella enteric
78 onucleotide (NaMN):5,6-dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella enteric
79 ized by nicotinate mononucleotide (NaMN):DMB phosphoribosyltransferases (CobT in Salmonella enterica)
80 nthetic enzyme complex anthranilate synthase-phosphoribosyltransferase, composed of the TrpD and TrpE
81    The structure represents a new fold for a phosphoribosyltransferase, consisting of three continuou
82 reased dosage of NPT1, encoding a nicotinate phosphoribosyltransferase critical for the NAD(+) salvag
83 ft loss in patients with undiagnosed adenine phosphoribosyltransferase deficiency and the need for im
84 ls led to accumulation of cells with adenine phosphoribosyltransferase deficiency and UPD.
85                                      Adenine phosphoribosyltransferase deficiency is a rare autosomal
86                        Patients with adenine phosphoribosyltransferase deficiency showed similar hist
87           We describe a patient with adenine phosphoribosyltransferase deficiency who was diagnosed d
88 eatures associated with hypoxanthine-guanine phosphoribosyltransferase deficiency.
89 agnosis of all forms of hypoxanthine-guanine phosphoribosyltransferase deficiency.
90 phoribosyltransferase (APRT) or nicotinamide phosphoribosyltransferase did not change the antiviral a
91 fic noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, does not alter glycolysis or
92  residues required for the reorganization of phosphoribosyltransferase domain "flexible loop" that le
93 nonucleotide:5,6-dimethylbenzimidazole (DMB) phosphoribosyltransferase (EC 2.4.2.21) enzyme that synt
94  a protein called extracellular nicotinamide phosphoribosyltransferase (eNampt; also known as pre-B c
95 identified a novel mannosylated glycoprotein phosphoribosyltransferase, encoded by Rv3242c from M. tu
96                       The reversible adenine phosphoribosyltransferase enzyme (APRT) is essential for
97 a decrease in expression of the nicotinamide phosphoribosyltransferase enzyme that recycles the nicot
98 NAD+ levels by interfering with nicotinamide phosphoribosyltransferase expression rendered tumor cell
99  similarities to other members of the type 1 phosphoribosyltransferase family but do not reveal the s
100 yeast fusion gene, cytosine deaminase/uracil phosphoribosyltransferase (FCU).
101 led that the functional domain has a type II phosphoribosyltransferase fold that may be a common arch
102 ified with the micronucleus and hypoxanthine phosphoribosyltransferase forward mutation assays.
103                                      Guanine phosphoribosyltransferase from Giardia lamblia, a key en
104 termined the crystal structure of nicotinate phosphoribosyltransferase from Themoplasma acidophilum (
105 urification of hypoxanthine-guanine-xanthine phosphoribosyltransferase from Thermus thermophilus (TtH
106                                      Orotate phosphoribosyltransferases from Plasmodium falciparum an
107          For the X-linked human hypoxanthine phosphoribosyltransferase gene (HPRT), this difference i
108 geted correction of a defective hypoxanthine phosphoribosyltransferase gene in hematopoietic progenit
109  black patients revealed that the nicotinate phosphoribosyltransferase gene, responsible for NAD bios
110 th and mutations at the hypoxanthine-guanine phosphoribosyltransferase gene.
111 le mutation rate of the hypoxanthine-guanine phosphoribosyltransferase gene.
112                                   Of the two phosphoribosyltransferase genes found in the H. pylori g
113                   By investigating candidate phosphoribosyltransferase genes in the genome, we determ
114 phosphoribosyltransferase (APRT) and guanine phosphoribosyltransferase (GPRT) that constitute the pri
115              Hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT) is crucial for the
116              Hypoxanthine-guanine-[xanthine] phosphoribosyltransferase (HG[X]PRT) is considered an im
117 ood inhibitors of human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Plasmodium falcipa
118 rines primarily through hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and xanthine phosphori
119  demonstrate that human hypoxanthine guanine phosphoribosyltransferase (HGPRT) converts T-705 into it
120                         Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is the key enzyme in p
121 y was determined at the hypoxanthine-guanine phosphoribosyltransferase (HGPRT) locus.
122 urine recycling enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGprt).
123  purine salvage enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
124 t salvage of guanine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
125 h LND and its variants (hypoxanthine-guanine phosphoribosyltransferase [HGprt]-related neurological d
126 phosphorylase (PNP) and hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) catalyze N-ribosidi
127            The hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRTase), a type I PRTase,
128 ine biosynthetic enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) cause the intractable n
129 toid cells in the human hypoxanthine-guanine-phosphoribosyltransferase (HPRT) gene and compared with
130  mouse ES cells having a mutant hypoxanthine phosphoribosyltransferase (Hprt) gene and grown on feede
131 moter and exon 1 of the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene in the mouse and h
132 e enzyme designed to target the hypoxanthine phosphoribosyltransferase (HPRT) gene located on human c
133  factor (VWF) and Flt-1, to the hypoxanthine phosphoribosyltransferase (Hprt) gene locus.
134 geted cells by co-targeting the hypoxanthine phosphoribosyltransferase (HPRT) gene.
135  functional, the complete human hypoxanthine phosphoribosyltransferase (HPRT) locus contained within
136                             The hypoxanthine phosphoribosyltransferase (Hprt) locus has been shown to
137 tion frequencies at the hypoxanthine guanine phosphoribosyltransferase (HPRT) locus in diploid human
138  with cRSS sites at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in peripheral T c
139  somatic mutation events at the hypoxanthine phosphoribosyltransferase (HPRT) locus in peripheral T l
140                   We found that hypoxanthine phosphoribosyltransferase (HPRT) mutation frequencies we
141 on the frequency of spontaneous hypoxanthine phosphoribosyltransferase (HPRT) mutations that can be d
142 sed by mutations of the hypoxanthine guanine phosphoribosyltransferase (HPRT) purine biosynthesis gen
143     Here we present the hypoxanthine-guanine phosphoribosyltransferase (HPRT) reporter gene mutationa
144 through the activity of hypoxanthine-guanine phosphoribosyltransferase (HPRT) to supply the cell with
145 romosomal disease gene encoding hypoxanthine phosphoribosyltransferase (HPRT), we monitor the relativ
146  mutations (Mfs) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT)-reporter gene in childr
147 oribosyltransferase (XGPRT) and hypoxanthine phosphoribosyltransferase (HPRT).
148 e purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT).
149 hromosome-linked enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT).
150                                 Hypoxanthine phosphoribosyltransferase (HPRT1) is a key enzyme in the
151 riant aspartic acid (Asp137) in hypoxanthine phosphoribosyltransferases (HPRTs) was examined by site-
152 salvage 6-oxopurines, including hypoxanthine phosphoribosyltransferases (HPRTs), are potential target
153 enes included those for hypoxanthine-guanine phosphoribosyltransferase (hpt), adenylosuccinate syntha
154 by the enzymes hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) and adenosine kinase
155 n of T. gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) in stable transgenic
156        Conversely, mice lacking nicotinamide phosphoribosyltransferase in hepatocytes exhibited impai
157 previously unrecognized role for a conserved phosphoribosyltransferase in NAD(+) biosynthesis.
158 f transcriptional repression of nicotinamide phosphoribosyltransferase in the NAD(+) salvage pathway.
159 tween the two families of ATP-PRTs and among phosphoribosyltransferases in general, we determined the
160                                          Two phosphoribosyltransferases in the purine salvage pathway
161 imiting enzyme in this pathway, nicotinamide phosphoribosyltransferase, increases total and mitochond
162 g [NAD(+)](i) by FK866-mediated nicotinamide phosphoribosyltransferase inhibition decreased the mitog
163 7.5 MBq, intravenously) or the nicotineamide phosphoribosyltransferase inhibitor GMX1778 (100 mg/kg/w
164 he slr0788 gene is a nicotinamide-preferring phosphoribosyltransferase involved in the first step of
165 idence indicates that PBEF is a nicotinamide phosphoribosyltransferase involved in the mammalian salv
166 l filtration experiments indicate that MtATP-phosphoribosyltransferase is a hexamer in solution, in t
167  MsmRv3242c infection models, we proved that phosphoribosyltransferase is involved in mycobacterial v
168 -ribose-1-diphosphate:decaprenyl-phosphate 5-phosphoribosyltransferase is known to be essential for t
169                 Visfatin/NAMPT (nicotinamide phosphoribosyltransferase) is a protein with several sug
170 nalysis has authenticated L. donovani uracil phosphoribosyltransferase (LdUPRT), an enzyme not found
171  the NAD salvage pathway enzyme nicotinamide phosphoribosyltransferase led to changes in NAD levels,
172 mbles bacterial ComF proteins and includes a phosphoribosyltransferase-like module.
173 alpha or Yalpha and the hypoxanthine guanine phosphoribosyltransferase locus (HPRT1).
174 eporter gene 5' of the X-linked hypoxanthine phosphoribosyltransferase locus in mouse embryonic stem
175  (Tg; inserted into the hypoxanthine-guanine phosphoribosyltransferase locus) that enables inducible
176 nock-in approach at the hypoxanthine-guanine phosphoribosyltransferase locus, we generated a transgen
177 potential new target is hypoxanthine-guanine phosphoribosyltransferase (MtHGPRT), a key enzyme of the
178                     In mammals, nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide monon
179 he NAD biosynthesis mediated by nicotinamide phosphoribosyltransferase (Nampt) and nicotinamide/nicot
180  pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeu
181 ss of cancer drugs that targets nicotinamide phosphoribosyltransferase (NAMPT) as a new strategy to i
182                                 Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the first ra
183 taining inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified
184 own-regulated expression of the nicotinamide phosphoribosyltransferase (Nampt) gene encoding the rate
185                                 Nicotinamide phosphoribosyltransferase (NAMPT) has been extensively s
186 enine dinucleotide (NAD(+)) via nicotinamide phosphoribosyltransferase (Nampt) has emerged as a media
187   We recently demonstrated that Nicotinamide phosphoribosyltransferase (Nampt) inhibition depletes in
188              Here, we show that nicotinamide phosphoribosyltransferase (NAMPT) inhibition suppresses
189 ion between PPM1D mutations and nicotinamide phosphoribosyltransferase (NAMPT) inhibition.
190  NAD+ depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) inhibition.
191     With the example of a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, we demonstr
192                                 Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme involv
193                                 Nicotinamide phosphoribosyltransferase (Nampt) is a promising antican
194                                 Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enz
195                                 Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enz
196                                 Nicotinamide phosphoribosyltransferase (Nampt) is a rate-limiting enz
197                                 Nicotinamide phosphoribosyltransferase (NAMPT) is highly evolved to c
198                                 Nicotinamide phosphoribosyltransferase (NAMPT) is located in both the
199 e NAD(+) salvage pathway, where nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting e
200                                 Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting e
201                                 Nicotinamide phosphoribosyltransferase (Nampt) is the rate-limiting e
202                                 Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting e
203 and analyzed adipocyte-specific nicotinamide phosphoribosyltransferase (Nampt) knockout (ANKO) and br
204 cell nuclear antigen (PCNA) and nicotinamide phosphoribosyltransferase (Nampt) levels.
205 s of SIRT1 protein, NAD(+), and nicotinamide-phosphoribosyltransferase (NAMPT) mRNA in several cell t
206 , we report that stimulation of nicotinamide phosphoribosyltransferase (NAMPT) produced robust neurop
207    NR supplementation decreases nicotinamide phosphoribosyltransferase (NAMPT) protein abundance in s
208 d compounds in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized
209  the NAD(+)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT) reduces liver NAD(+) l
210                           Human nicotinamide phosphoribosyltransferase (NAMPT) replenishes the NAD po
211   One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production
212                                 Nicotinamide phosphoribosyltransferase (NAMPT) upregulation in human
213 on of NAD+ biosynthesis enzyme, nicotinamide phosphoribosyltransferase (NAMPT) via myocyte enhancer f
214 lony-enhancing factor (PBEF) or nicotinamide phosphoribosyltransferase (Nampt)) is a pleiotropic medi
215 ere raised by observations that nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in mamma
216 de increase their expression of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD(+
217                                 Nicotinamide phosphoribosyltransferase (NAMPT), an adipokine that pla
218               Protein levels of nicotinamide phosphoribosyltransferase (NAMPT), an essential NAD(+) b
219 nucleotide (NAD+) biosynthesis, nicotinamide phosphoribosyltransferase (NAMPT), and levels of NAD+ di
220 nhibitors, specifically against nicotinamide phosphoribosyltransferase (NAMPT), as preclinical studie
221 bition with FK866 of the enzyme nicotinamide phosphoribosyltransferase (NAMPT), catalyzing the first
222 adenylyltransferase (NMNAT) and nicotinamide phosphoribosyltransferase (NAMPT), mainly replenishes NA
223 gnificant decrease of SIRT1 and nicotinamide phosphoribosyltransferase (NAMPT), SIRT1 activity and ph
224 e NAD(+) salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT), synergizes with MMS t
225             We demonstrate that nicotinamide phosphoribosyltransferase (Nampt), the equivalent enzyme
226 is derivative was found to bind nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enz
227  show that levels of NAD(+) and nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enz
228 d pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enz
229  sustained endotoxin tolerance, nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enz
230 ates the myeloid cell levels of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enz
231              Here, we show that nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enz
232                 Here, we report nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting ste
233 tment reduced the expression of nicotinamide phosphoribosyltransferase (NAMPT), thus limiting IDH2 ac
234 and we found that inhibition of nicotinamide phosphoribosyltransferase (Nampt), which synthesizes sub
235 om nicotinamide is performed by nicotinamide phosphoribosyltransferase (Nampt).
236 ethyl)benzamide (CB38065, 1) is nicotinamide phosphoribosyltransferase (Nampt).
237 e NAD(+) salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT).
238 ion on lysine 74 and 78 via the nicotinamide phosphoribosyltransferase (NAMPT)/sirtuin 2 (SIRT2) path
239 synthesis to exclusive usage of nicotinamide phosphoribosyltransferase (NamPT); 2) the occurrence of
240                           Human nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12) catalyzes
241 tracellular enzymatic activity (nicotinamide phosphoribosyltransferase, Nampt) leading to NAD synthes
242 wly described endolysosomal activities of NA phosphoribosyltransferase (NAPRT) and NMN adenyltransfer
243 motes epigenetic silencing of nicotinic acid phosphoribosyltransferase (NAPRT), a key gene involved i
244 re, we show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a second NAD(+)-produ
245 g the NAD+ salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1), sensitizing to NAD+
246 rate by the NAD(+) salvage pathway enzyme NA phosphoribosyltransferase (Npt1).
247 ic pathway including NtPMT1a and quinolinate phosphoribosyltransferase (NtQPT2), and lowers nicotine
248  needed for drugs targeting the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi, etiologi
249 izing effects of inhibition of nicotineamide phosphoribosyltransferase on (177)Lu-DOTATATE treatment
250  (UMP) biosynthesis are catalyzed by orotate phosphoribosyltransferase (OPRT) and orotidine 5'-monoph
251                                      Orotate phosphoribosyltransferase (OPRT) is an indispensible com
252                                      Orotate phosphoribosyltransferases (OPRT) catalyze the formation
253  kinetic mechanism ascribed to yeast orotate phosphoribosyltransferase (OPRTase) has been shown to be
254                                      Orotate phosphoribosyltransferase (OPRTase, EC 2.4.2.10) catalyz
255                                      Orotate phosphoribosyltransferases (OPRTs) form and break the N-
256                                 Nicotinamide phosphoribosyltransferase overexpressing mice were mildl
257 alciparum (Pf) hypoxanthine-guanine-xanthine phosphoribosyltransferase (PfHGXPRT).
258                  Two putative nicotinic acid phosphoribosyltransferases, PncB1 (Rv1330c) and PncB2 (R
259 both nicotinic acid and quinolinic acid (QA) phosphoribosyltransferases (PRTase) despite low sequence
260          Unlike most PRT proteins, which are phosphoribosyltransferases (PRTases), PurR lacks catalyt
261 m (Pf) and Plasmodium vivax (Pv) 6-oxopurine phosphoribosyltransferases (PRTs).
262                                  Quinolinate phosphoribosyltransferase (QAPRTase, EC 2.4.2.19) cataly
263                                  Quinolinate phosphoribosyltransferase (QAPRTase, EC 2.4.2.19) cataly
264                              Quinolinic acid phosphoribosyltransferase (QAPRTase, EC 2.4.2.19) forms
265 lastic astrocytes, expressed quinolinic acid phosphoribosyltransferase (QPRT) to use quinolinic acid
266           Because a required quinolinic acid phosphoribosyltransferase (QPRTase) is not encoded in it
267 R, B. caldolyticus PyrR catalyzes the uracil phosphoribosyltransferase reaction but with maximal acti
268 ysis, demonstrate unique overlapping ATP and phosphoribosyltransferase sites, and establish reaction
269 ctural neighbors to APRTases are the orotate phosphoribosyltransferases, suggesting different paths o
270 er reports of Ping Pong kinetics for various phosphoribosyltransferases that do not form the phosphor
271 nly in muscle by overexpressing nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in t
272 . maripaludis hpt gene encoding hypoxanthine phosphoribosyltransferase to confer sensitivity to the b
273             Moreover, targeting nicotinamide phosphoribosyltransferase to the mitochondria also enhan
274                                  These novel phosphoribosyltransferase transition states are similar
275 how high structural homology to anthranilate phosphoribosyltransferase (TrpD) and nucleoside phosphor
276 was reconstituted in vitro with anthranilate phosphoribosyltransferase (TrpD), threonine dehydratase
277 ned that the conserved uridine monophosphate phosphoribosyltransferase (UMPS), which acts in pyrimidi
278                                       Uracil phosphoribosyltransferase (UPP) catalyzes the initial st
279 tively encode uridine kinase (UK) and uracil phosphoribosyltransferase (UPRT) bifunctional enzymes we
280 e combination of spatially restricted uracil phosphoribosyltransferase (UPRT) expression with 4-thiou
281                                       Uracil phosphoribosyltransferase (UPRT) is a member of a large
282                                       Uracil phosphoribosyltransferase (UPRT) is a pyrimidine salvage
283             Cre-induced expression of uracil phosphoribosyltransferase (UPRT) provides spatial specif
284 l (TU) in cells expressing transgenic uracil phosphoribosyltransferase (UPRT), a method known as TU-t
285 st enzyme in pyrimidine biosynthesis, uracil phosphoribosyltransferase (UPRT), a salvage enzyme, or b
286  mice that express cell-type-specific uracil phosphoribosyltransferase (UPRT), an enzyme required for
287 herichia coli cytosine deaminase (CD)/uracil phosphoribosyltransferase (UPRT).
288               PyrR also catalyzes the uracil phosphoribosyltransferase (UPRTase) reaction even though
289 ss I homologue) and HPRT (human hypoxanthine phosphoribosyltransferase), was accomplished.
290 uanosine deaminase, and hypoxanthine guanine phosphoribosyltransferase, we demonstrate that purine nu
291 hosphoribosyltransferase and of hypoxanthine phosphoribosyltransferase were the same in extracts from
292 lucuronidase and a cytosine deaminase/uracil phosphoribosyltransferase, which activate the prodrugs 9
293 63), in contrast to the hypoxanthine-guanine phosphoribosyltransferases, which use two Mg2+ ions; and
294       G. lamblia expresses an unusual purine phosphoribosyltransferase with a high specificity for gu
295 two purine salvage enzymes: xanthine-guanine phosphoribosyltransferase (XGPRT) and hypoxanthine phosp
296 phyla Firmicutes and Bacteroidetes, xanthine phosphoribosyltransferase (XPRT) is a purine salvage enz
297 sphoribosyl-transferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT) using gene replacement
298            Recombinant LdPEX5 bound xanthine phosphoribosyltransferase (XPRT), a PTS-1 containing gly
299 osphoribosyltransferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT).
300 9) mutants), yeast cytosine deaminase:uracil phosphoribosyltransferase (yCD:UPRT) and nitroreductase

 
Page Top